STXS · Stereotaxis, Inc.

Track STXS — free

$1.18 +0.00 (+0.00%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$130.26M

100.20M

Volume · Oct 5 505.23K Avg daily vol (3M) 822.14K

Up next

Next earnings call

Nov 23, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Aug 12, 2026

Q2 2026 earnings call transcript

call held Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-61.2%

Trailing year

Short interest

5.6%

Latest settlement · 10.1 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 11, 2026

Q2 FY26

TL;DR. Stereotaxis reported Q2 revenue of $7.7M and provided quarterly guidance of ~$7M/$8M in recurring revenue and ~$3M/$3M in system revenue for Q3/Q4, targeting cash flow profitability in 1H 2027, while highlighting early commercial wins including the first US GenesisX purchase, initial Synchrony system sales, and robotic catheter revenue surpassing $1M with 270% sequential growth.

Bullish

+ Management issued quarterly guidance for strong recurring revenue ramp to ~$7M in Q3 and ~$8M in Q4, and targets cash flow profitability in 1H 2027.
+ Received and shipped multiple Synchrony systems following FDA clearance in April, with a path to over $1M per quarter and several hospitals considering standardizing their cath labs on Synchrony.
+ Company maintains a clean balance sheet with $10.5M cash, no debt, and confidence in advancing strategy without substantial dilution.

Bearish

− Q2 system revenue of $1.5M declined sharply year-over-year due to no robotic system delivery in the quarter.
− Operating loss and net loss widened year-over-year, and adjusted operating loss and adjusted net loss also increased.
− Gross margins remain depressed at 58% overall (66% recurring, 29% system) due to low manufacturing volume, expected to persist over the next few quarters.
− Robotic catheter growth remains supply-constrained with a backlog of catheter orders, limiting near-term revenue recognition.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −36%

below

Price vs 50-day avg −12%

below

RSI (14) 32

neutral

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −15%

trailing

6-month return −42%

trailing

YTD return −49%

this year

Relative strength −53%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Distributing

2 of 108 funds reported for Sep 30 · net -467 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.57% of float · ▲ +10.4% MoM · 10.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

108 holders — mid 3-yr range

Squeeze score 65

elevated · 0–100

Fundamentals

Strong

Revenue growth −6%

Y/Y

Gross margin 58%

expanding

EPS growth +17%

Y/Y

Balance sheet $41.8M

net cash

Quant / Vol

risk profile

Very High

Volatility 53%

annualized · 1-yr

Max drawdown −67%

past year

ATR 5.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 11, 2026

third quarter of this year

Recurring revenue $7M

fourth quarter of this year

Recurring revenue $8M

third quarter

System revenue $3M

fourth quarter

System revenue $3M

Guided vs delivered · last 1 settled

Revenue first quarter of 2024

guided $7M

guided $7M $6.88M Miss −1.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−36% Bearish

Price vs 50-day avg

−12% Bearish

RSI (14)

32 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Distributing

2 of 108 funds reported for Sep 30 · net -467 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.57% of float · ▲ +10.4% MoM · 10.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

108 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $1 · 0% Range high $4

vs 200-day avg -36% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted net loss non-GAAP	-$2M	second quarter of 2026	—
Adjusted operating expenses non-GAAP	$6.6M	second quarter of 2026	—
Adjusted operating loss non-GAAP	-$2.1M	second quarter of 2026	—
Free cash flow non-GAAP	-$3.7M	second quarter of 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
STXS Stereotaxis, Inc. this stock	$130.26M	-48.7%	-5.8%	—	5.6%
ISRG Intuitive Surgical Inc	$143.14B	-28.2%	+20.5%	46.5	2.3%
BDX Becton Dickinson & Co	$49.57B	—	+8.2%	—	4.2%
MDLN Medline Inc.	$45.62B	-14.8%	+11.5%	—	3.1%
RMD Resmed Inc	$32.02B	-7.5%	+13.4%	21.3	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

107

% held: 43.0%
Reported: 2 of 108
Top holder: DAFNA Capital Management…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

5.6M

Days to cover: 10.1d
Change: +525.1K sh

View

Short Volume

Short vol %

72%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

479

Value: $632
As of: Sep 10, 2026

View

Off-Exchange

Off-exchange %

51.8%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$32.4M

Net income (FY): $-21.6M
EPS diluted: $-0.25

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 12, 2026
This year: 12

View

Exempt Offerings

Offering

Indefinite

Filed: Aug 15, 2024

View

Earnings & Events

Webcasts

Last webcast

Aug 11, 2026

View

Performance

	5D	20D	120D	MTD	YTD
STXS	-6.4%	-15.1%	-41.9%	-4.1%	-48.7%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-7.6%	-15.7%	-53.4%	-5.7%	-62.3%

Key facts CIK 1289340 CUSIP 85916J409 13F (30d) 4 filings 4 filers Visit website Investor relations

STXS · Stereotaxis, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance